Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy

Inclusion Criteria: * Voluntarily signed informed consent form; * Age ≥ 18 years; * No restrictions on sex; * Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Exclusion Criteria: * Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \> 1.5 × ULN), or psychiatric disorders. * Deemed unsuitable for participation in the study at the discretion of the investigators.